Literature DB >> 9179912

Technetium-MIBI as a glioma imaging agent for the assessment of multi-drug resistance.

D W Andrews1, R Das, S Kim, J Zhang, M Curtis.   

Abstract

OBJECTIVE: To explore the presence of MDR-1 drug resistance in human glioma utilizing a Single Photon Emission Computerized Tomography (SPECT) imaging agent, sesta-MIBI, and testing cases interpreted as positive for drug resistance with molecular characterization of subsequent tissue biopsy, including RNA, Northern blot analysis, and polymerase chain reaction, and in situ hybridization.
METHODS: Six patients that carried a diagnosis of biopsy-proven glioma underwent dual isotope SPECT imaging with thallium 201 and technetium sesta-MIBI. All six patients underwent subsequent surgical reexcision of their tumors, and tissue was immediately flash frozen for further analysis. PolyA RNA was isolated and subsequently analyzed by both Northern blot analysis and RT-PCR utilizing an MDR-1 probe (ATCC) and MDR-1 primers.
RESULTS: Four patients with SPECT concordance yielded tumors without MDR-1 expression whereas two patients with SPECT discordance yielded tumors with MDR-1 gene expression. In one discordant case we subsequently performed RT-PCR in situ amplification/ hybridisation and immunohistochemistry with, respectively, an MDR-1 sense primer with Biotin labeled probes and an MDR-1 monoclonal antibody, and both analyses revealed MDR-1 expression in tumor cells.
CONCLUSION: These data support the use of SPECT technetium sesta-MIBI to evaluate the presence of MDR-1 gene expression in gliomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9179912     DOI: 10.1097/00006123-199706000-00047

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  5 in total

1.  Glioma residual or recurrence versus radiation necrosis: accuracy of pentavalent technetium-99m-dimercaptosuccinic acid [Tc-99m (V) DMSA] brain SPECT compared to proton magnetic resonance spectroscopy (1H-MRS): initial results.

Authors:  Amr Amin; Hosna Moustafa; Ebaa Ahmed; Mohamed El-Toukhy
Journal:  J Neurooncol       Date:  2011-09-13       Impact factor: 4.130

2.  Influence of glioma's multidrug resistance phenotype on (99m)Tc-tetrofosmin uptake.

Authors:  George A Alexiou; Anna Goussia; Athanasios P Kyritsis; Spyridon Tsiouris; Antigoni Ntoulia; Vassiliki Malamou-Mitsi; Spyridon Voulgaris; Andreas D Fotopoulos
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

3.  Correlation of expression of multidrug resistance protein and messenger RNA with 99mTc-methoxyisobutyl isonitrile (MIBI) imaging in patients with hepatocellular carcinoma.

Authors:  Hai Wang; Xiao-Ping Chen; Fa-Zu Qiu
Journal:  World J Gastroenterol       Date:  2004-05-01       Impact factor: 5.742

4.  Expression of multidrug resistance protein gene in patients with glioma after chemotherapy.

Authors:  T Abe; T Mori; Y Wakabayashi; M Nakagawa; S P Cole; K Koike; M Kuwano; S Hori
Journal:  J Neurooncol       Date:  1998-10       Impact factor: 4.130

5.  Bromocriptine enhances the uptake of (99m)Tc-MIBI in patients with hepatocellular carcinoma.

Authors:  Xiangting Chai; Qiaoyu Liu; Wenyu Shao; Feng Zhang; Xuehao Wang; Hai Wang
Journal:  J Biomed Res       Date:  2012-04-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.